Market Overview

UPDATE: Wunderlich Securities Initiates LSI Corporation at Buy on Upside Potential

Share:

Wunderlich Securities initiated coverage on LSI Corporation (NASDAQ: LSI) with a Buy rating and a $9 price target.

Wunderlich Securities noted, "We believe the company is positioned to outperform its peers in 2013 due to: 1) the early move into the NAND Flash solid-state storage (SSS) markets with the company's Flash Storage Processor (FSP) and PCIe Flash Adapters (PFA), which should position LSI to benefit from the strong growth expected in this market; 2) the company's Storage systems and Server markets benefiting from the transition from 6 gig to 12 gig SAS expected to continue in 2013; and 3) design wins with its Axxia SoC solutions transitioning to production in the wireless infrastructure segment and this should help offset the challenging HDD market until a recovery later in 2013."

LSI Corporation closed at $6.91 on Thursday.

Latest Ratings for LSI

DateFirmActionFromTo
Oct 2019UpgradesHoldBuy
Oct 2019UpgradesHoldBuy
Oct 2019MaintainsOverweight

View More Analyst Ratings for LSI
View the Latest Analyst Ratings

Posted-In: Wunderlich SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (LSI)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WEEDMKM PartnersMaintains30.0
NKTRH.C. WainwrightMaintains32.0
DISCARosenblattMaintains33.0
GOODNational SecuritiesInitiates Coverage On25.0
XOGCitiDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

Mylan Announces Famy Care Received Final FDA Approval for ANDA for Levonorgestrel, Ethinyl Estradiol Tablets